4/8
08:10 am
iva
Inventiva S.A. (NASDAQ: IVA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $12.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Inventiva S.A. (NASDAQ: IVA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $12.00 to $20.00. They now have a "buy" rating on the stock.
4/3
04:03 pm
iva
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F [Yahoo! Finance]
Low
Report
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F [Yahoo! Finance]
4/3
04:00 pm
iva
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
Low
Report
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
4/1
02:34 pm
iva
Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
4/1
08:09 am
iva
Inventiva S.A. (NASDAQ: IVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Low
Report
Inventiva S.A. (NASDAQ: IVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
3/28
03:05 am
iva
Inventiva announces the nomination of Andre Turenne as Director [Yahoo! Finance]
Medium
Report
Inventiva announces the nomination of Andre Turenne as Director [Yahoo! Finance]
3/28
03:00 am
iva
Inventiva announces the nomination of Andre Turenne as Director
Medium
Report
Inventiva announces the nomination of Andre Turenne as Director
3/27
04:09 pm
iva
Inventiva reports its 2023 full-year results [Yahoo! Finance]
Medium
Report
Inventiva reports its 2023 full-year results [Yahoo! Finance]
3/27
04:00 pm
iva
Inventiva reports its 2023 full-year results
Medium
Report
Inventiva reports its 2023 full-year results
3/22
04:17 pm
iva
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results [Yahoo! Finance]
Low
Report
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results [Yahoo! Finance]
3/22
04:00 pm
iva
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
Low
Report
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
3/20
08:32 am
iva
Inventiva S.A. (NASDAQ: IVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Medium
Report
Inventiva S.A. (NASDAQ: IVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
3/18
05:49 pm
iva
Inventiva Phase 2 study for MASH drug meets primary endpoint [Seeking Alpha]
High
Report
Inventiva Phase 2 study for MASH drug meets primary endpoint [Seeking Alpha]
3/18
04:12 pm
iva
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D [Yahoo! Finance]
High
Report
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D [Yahoo! Finance]
3/18
04:00 pm
iva
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
High
Report
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
3/13
04:00 pm
iva
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
Low
Report
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
3/8
01:49 pm
iva
Inventiva resumes Phase 3 study for NASH drug, stock up 6% [Seeking Alpha]
Low
Report
Inventiva resumes Phase 3 study for NASH drug, stock up 6% [Seeking Alpha]
3/7
04:09 pm
iva
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed [Yahoo! Finance]
Low
Report
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed [Yahoo! Finance]
3/7
04:00 pm
iva
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
Medium
Report
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
2/22
05:25 pm
iva
Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause [Seeking Alpha]
Low
Report
Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause [Seeking Alpha]
2/16
02:01 pm
iva
Inventiva drops after adverse event in Phase 3 trial for NASH drug [Seeking Alpha]
Neutral
Report
Inventiva drops after adverse event in Phase 3 trial for NASH drug [Seeking Alpha]
2/16
10:43 am
iva
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at Stifel Nicolaus from $27.00 to $25.00. They now have a "buy" rating on the stock.
Low
Report
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at Stifel Nicolaus from $27.00 to $25.00. They now have a "buy" rating on the stock.
2/16
07:30 am
iva
Inventiva Stock Falls 20% After Pausing Screening, Randomization in Trial Due to Adverse Event [MarketWatch]
Neutral
Report
Inventiva Stock Falls 20% After Pausing Screening, Randomization in Trial Due to Adverse Event [MarketWatch]
2/15
04:38 pm
iva
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 [Yahoo! Finance]
High
Report
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 [Yahoo! Finance]
2/15
04:35 pm
iva
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
High
Report
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3